Comparison of CBV, BEAM and BEAC high‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non‐Hodgkin lymphoma: Efficacy and toxicity

• DOI: 10.1111/ajco.12610
• Publication Date: 2017-01-19T14:52:33Z
• Authors: Youwu Shi; Peng Liu; Shengyu Zhou; Jianliang Yang; Xiaohong Han; Xiaohui He; Changgong Zhang; Lin Gui; Yan Qin; Sheng Yang; Liya Zhao; Jiarui Yao; Bo Jia; Shuxiang Zhang; Yan Sun; Yuankai Shi
• Keywords: Carmustine; Melphalan; Mucositis

Limited data are available to guide the choice of conditioning regimen before autologous hematopoietic stem cell transplantation (AHSCT) for patients with lymphoma.We analyzed 129 non-Hodgkin lymphoma who underwent AHSCT from 1996 2013 using most common regimens: CBV (cyclophosphamide, carmustine and etoposide; n = 16), BEAM (carmustine, etoposide, cytarabine melphalan; 36) BEAC cyclophosphamide; 77).At a median follow-up 42.5 months, estimated 5-year overall survival CBV, groups was 68.8%, 77.8% 81.8%, respectively (P 0.584). The progression-free in group (43.8%) relatively inferior (66.7%) (67.5%) groups, but differences were not significant 0.403). Grade 2 or higher mucositis, diarrhea fever more < 0.05). No observed time recovery duration hospitalization. amount transfused platelet significantly less CBV.CBV, regimens all optional high-dose chemotherapy NHL patients.